Append Medical Completes $7.4M Million Series A Round

Append Medical, developer of the first no metal implant minimally invasive solution for transcatheter Left Atrial Appendage (LAA) exclusion, today announced the completion of a $7.4 million Series A financing round.

The round will enable the company to complete development and perform its first clinical trial.

Originally developed based on the research of Prof. Leonid Sternik from the Sheba Medical Center, the company was founded and led by Dr. Zachi Berger with seed investment from the MEDX Xelerator, a leading MedTech incubator in Israel.

“Append Medical brings an important innovation to the field of stroke prevention in atrial fibrillation patients,” explains Prof. Horst Sievert. “Its suture delivery system is the first ever to allow for minimally invasive endovascular exclusion of the left atrial appendage leaving only a suture lasso behind and no metal implant.”

The financing round was led by MedTecX LP along with an unnamed strategic company and other investors and included a $700K of matching grant from the Israel Innovation Authority.

“This round will enable Append to continue developing its technology towards a clinical product. We are thrilled to see the accomplishment of the team so far,” noted Shai Policker, CEO of the MEDX Xelerator and Append’s Chairman.

“The growing problem of atrial fibrillation and the issues associated with anticoagulants calls for innovation and we are happy to take part in supporting this important technology,” added Lifei Cheng, CEO of MedTecX.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

“We are excited to begin our journey as a public company with this additional investment. We believe Tevogen’s patient-centric approach, which merges a focus on affordability with advanced science, is a blueprint for sustainable success in the current era of healthcare. I am pleased that investors now have the opportunity to participate in Tevogen’s mission to become the very first life science company offering commercially attractive and affordable personalized T cell therapies for large patient populations in virology, oncology, and neurology, said the CEO of Tevogen Bio.
MB2 Dental notes the financing will be used to fund upcoming acquisitions and future growth for the company, following a record year of growth in 2023 with 150 new partnerships.
Procyrion notes the funding will support the DRAIN-HF pivotal IDE trial evaluating the company's Aortix pump, internal R&D programs to improve manufacturability, and commercialization preparation.
PhotoniCare, in January of this year, announced that the U.S. Food and Drug Administration had granted clearance for its TOMi™ Scope for non-invasive imaging of the middle ear.
Vicarious Surgical added Philip Liang and Ric Fulop to their Board of Directors. 

By using this website you agree to accept Medical Device News Magazine Privacy Policy